These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 4701654)

  • 1. Histochemical and biochemical investigation of advanced prostatic carcinoma treated with estramustine phosphate, Estracyt.
    Nilsson T; Müntzing J
    Scand J Urol Nephrol; 1973; 7(1):18-22. PubMed ID: 4701654
    [No Abstract]   [Full Text] [Related]  

  • 2. Histochemical and biochemical enzyme studies in prostatic carcinomatous tissue before and during treatment with estrogen.
    Nilsson T; Müntzing J
    Scand J Urol Nephrol; 1973; 7(1):14-7. PubMed ID: 4701653
    [No Abstract]   [Full Text] [Related]  

  • 3. Some biochemical and histochemical aspects in hyperplasia and carcinoma of the human prostate.
    Nilsson T; Müntzing J
    J Surg Oncol; 1973; 5(3):205-14. PubMed ID: 4712286
    [No Abstract]   [Full Text] [Related]  

  • 4. Inhibitory effects of Estracyt on R-3327 rat prostatic carcinoma.
    Müntzing J; Kirdani RY; Saroff J; Murphy GP; Sandberg AA
    Urology; 1977 Nov; 10(5):439-45. PubMed ID: 919134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyproterone acetate in the treatment of advanced carcinoma of the prostate.
    Smith RB; Walsh PC; Goodwin WE
    J Urol; 1973 Jul; 110(1):106-8. PubMed ID: 4713345
    [No Abstract]   [Full Text] [Related]  

  • 6. Estramustine phosphate therapy in poorly differentiated carcinoma of the prostate.
    Edsmyr F; Esposti PL; Andersson L
    Scand J Urol Nephrol Suppl; 1980; 55():139-42. PubMed ID: 6938017
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Variable erythrokeratodermias. Enzyme histochemical and autoradiographic studies in 2 cases].
    Schellander F; Fritsch P
    Arch Klin Exp Dermatol; 1969; 235(3):241-51. PubMed ID: 4243196
    [No Abstract]   [Full Text] [Related]  

  • 8. The prognostic value of acid phosphatase and beta-glucuronidase activity in biopsy specimens from patients with reactivated prostatic cancer.
    Nilsson T; Müntzing J
    Scand J Urol Nephrol; 1975; 9(3):205-7. PubMed ID: 1209176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Enzyme histochemical studies of the salt gland of ducks (Anas platyrhynchus). II. Cytochemical localization of some hydrolases].
    Kühnel W; Petry G; Burock G
    Z Zellforsch Mikrosk Anat; 1969; 99(4):560-9. PubMed ID: 4311299
    [No Abstract]   [Full Text] [Related]  

  • 10. [Treatment of advanced carcinoma of the prostate with Estracyt (author's transl)].
    Nagel R; Kölln CP
    Med Klin; 1976 Oct; 71(41):1724-8. PubMed ID: 824540
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of advanced prostatic carcinoma with estramustine phosphate (Estracyt).
    Jönsson G; Högberg B; Nilsson T
    Scand J Urol Nephrol; 1977; 11(3):231-8. PubMed ID: 339329
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma concentrations of estramustine phosphate and its major metabolites in patients with prostatic carcinoma treated with different doses of estramustine phosphate (Estracyt).
    Gunnarsson PO; Forshell GP; Fritjofsson A; Norlén BJ
    Scand J Urol Nephrol; 1981; 15(3):201-5. PubMed ID: 7323739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enzymes in fibroblastic lesions: a histochemical and quantitative survey of alkaline and acid phosphatase, beta-glucuronidase, non-specific esterase and leucine aminopeptidase in benign and malignant fibroblastic lesions of bone and soft tissue.
    Jeffree GM
    J Bone Joint Surg Br; 1972 Aug; 54(3):535-46. PubMed ID: 4506232
    [No Abstract]   [Full Text] [Related]  

  • 14. Carcinoma of the prostate. I. Histochemical examination as an aid in evaluating prostate carcinoma.
    Vrubel F; Mráz J; Nĕmecek R; Papousek F; Hanselová M
    Int Urol Nephrol; 1979; 11(4):295-9. PubMed ID: 536178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Treatment of advanced metastasizing carcinoma of the prostate with estracyt (author's transl)].
    Rambausek M; Lutherer S; Terhorst B
    Urologe A; 1981 Jul; 20(4):223-7. PubMed ID: 7196632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic usefulness of serum acid phosphatase levels in carcinoma of the prostate.
    Ishibe T; Usui T; Nihira H
    J Urol; 1974 Aug; 112(2):237-40. PubMed ID: 4843340
    [No Abstract]   [Full Text] [Related]  

  • 17. Uptake of estramustine phosphate (estracyt) metabolites in prostatic cancer.
    Norlén BJ; Andersson SB; Björk P; Gunnarsson PO; Fritjofsson A
    J Urol; 1988 Nov; 140(5):1058-62. PubMed ID: 3172360
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A rat prostatic adenocarcinoma as a model for the human disease.
    Müntzing J; Kirdani RY; Murphy GP; Sandberg AA
    Invest Urol; 1979 Jul; 17(1):37-41. PubMed ID: 447485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of advanced prostatic carcinoma with Estracyt. A preliminary report.
    Jönsson G; Högberg B
    Scand J Urol Nephrol; 1971; 5(2):103-7. PubMed ID: 5093102
    [No Abstract]   [Full Text] [Related]  

  • 20. [Leucyl-aminopeptidase, thioacetic acid esterase and E 600-resistant esterase in cervix uteri cancer].
    Waroński W
    Zentralbl Gynakol; 1966 Jan; 88(3):66-71. PubMed ID: 4167682
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.